From Health Canada:
...As of June 7, 2006, Boehringer Ingelheim (BI) has received 14 reports of intracranial hemorrhage (ICH), including 8 fatalities, in 6840 HIV-1 infected patients receiving APTIVUS in clinical trials...
for the Public
for Health Professionals
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment